CA-NEXON-AMERICA
MapleStory M , the free-to-play, massively multiplayer online mobile game for iOS and Android , is ringing in the new year with its biggest update yet - the introduction of the legendary Hero Shade with a variety of limited-time events.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200116005227/en/
One of the most celebrated Heroes in Maple World, Shade is one of Six Heroes ending the sinister reign of MapleStory’s biggest antagonist, the Black Mage. The last Hero to be added to the MapleStory M universe, Shade is classified as a Pirate with a powerful force, using primary and secondary weapons of Knuckles and Fox Marbles to conquer enemies. Now reborn and, with the spirit world at his fingertips, he is investigating claims of the Black Mage’s return.
The update delivers an array of events to celebrate the new Hero Shade as well as Lunar New Year! Starting today, exciting level-up events will be available including:
- Shade Growth Support Event: Until February 24, players who reach a certain level will receive additional in-game items useful for a specific character’s level-up.
- Shade Burning Event: Any new Shade character can be leveled-up by three levels for every level up within level 3 to 100 until February 10.
- Shade Celebratory Log-in Reward Event: Players logging-in from today through January 22 will receive a special gift to help their character level up once per account.
- Heroes M Events: Through February 11, four different types of events are going to be held in honor of the Six legendary Heroes. Any characters or players with those Six Heroes will be rewarded with items to help boost experience as well as obtain additional stat options for their characters.
Along with the level-up events, there’s a bevy of Lunar New Year-themed events including:
- Lunar New Year 7 Day Attendance Event: Between January 20 and February 3, participating players who log-in will claim attendance rewards for items that give their characters experience points.
- Lunar New Year Achievement Event: Starting January 20 and ending February 3, players collect unique coins to earn rewards including an item that can assist with Starforce Reinforcement, Character Decorate item, and EXP Boost item.
To learn more about MapleStory M, visit the Google Play or App Store page and follow @PlayMapleM on Twitter for the latest updates.
Assets :
Social Media: Twitch / Facebook / Twitter / YouTube / Discord
About MapleStory M smarturl.it/110rng
MapleStory M, launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory to mobile, offering the same endless amount of customization, immersive storylines and epic boss raids that fans have come to expect from the epic franchise. Available in 140 countries and 9 languages, MapleStory M quickly reached 10 million downloads within 100 days after global launch.
About Nexon America Inc. http://www.nexon.net/corporate/about-nexon/
Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO) with more than 80 live games operated across more than 190 countries, is a global leader in online games. Nexon America introduced micro-transactions and the free-to-play business model in the Western market and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Nexon is listed on the Tokyo Stock Exchange, and the company was placed on the Nikkei Stock Index 300 in 2017.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005227/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
